Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on January 27, 2026, reports on the Notice and Proxy Statement for an Extraordinary General Meeting of Shareholders scheduled for March 5, 2026. Redhill Biopharma Ltd. is a foreign private issuer headquartered in Tel Aviv, Israel. The filing does not contain financial results for a specific reporting period but focuses on corporate governance actions requiring shareholder approval.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses on capital structure and equity compensation:
- Outstanding Equity: As of the record date (January 23, 2026), the Company had 51,128,851,000 Ordinary Shares outstanding, represented by 5,112,885 ADSs.
- Authorized Capital: Currently NIS 1,600,000,000 (159,994,000,000 Ordinary Shares and 6,000,000 Preferred Shares).
- Available Shares: Approximately 90,575,040,000 Ordinary Shares were available for future issuance as of the record date.
Material Changes and Proposals
Shareholders are asked to vote on four specific proposals:
- Non-Executive Director RSUs: Approval to grant Restricted Share Units (RSUs) to four non-executive directors. Grants range from 9,000 to 12,500 ADSs per director, vesting quarterly over two years.
- CEO RSUs: Approval to grant 38,000 ADSs in RSUs to Dror Ben-Asher (CEO and Chairman). This represents approximately 0.55% of total outstanding equity on a fully diluted basis. Approval requires a "Special Majority" vote from non-controlling shareholders.
- CCO RSUs: Approval to grant 27,000 ADSs in RSUs to Rick D. Scruggs (Chief Commercial Officer and Director). This represents approximately 0.39% of total outstanding equity on a fully diluted basis.
- Capital Increase: Approval to increase authorized share capital from NIS 1.6 billion to NIS 5.0 billion. This would increase the number of authorized Ordinary Shares to 499,994,000,000.
Outlook, Risks, and Management Commentary
Management states that the proposed increase in authorized share capital is necessary due to an overall decrease in the market price of the Company's ADSs. The Board believes this increase is required to ensure sufficient capital is available to pursue financing, execute potential acquisitions, or make future equity grants without undue delay. The filing notes that the Company is subject to Israeli Companies Law regarding related-party transactions and voting thresholds for executive compensation.
Investor Verification Checklist
- Verify the current market price of ADSs to assess the dilution impact of the proposed capital increase and RSU grants.
- Confirm the voting threshold requirements for Proposal 2 (CEO compensation), which requires a special majority of non-controlling shareholders.
- Review the Company's most recent Form 20-F or 6-K for actual financial performance, as this filing contains no revenue or cash flow data.
- Check the Company's website for any Position Statements submitted by shareholders prior to the February 23, 2026 deadline.